News Sentiment

HRMY sentiment intelligence

Harmony Biosciences Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 33.28 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-3.4% over one week, +10.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Harmony Biosciences Stock - Analyst consensus and technical backdrop

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -3.4% Price reacting lower
Trend fit Trend inactive 10.4% over four weeks
Fair value 1.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 11
simplywall.st 10
TradingKey 3
Stock Traders Daily 2
Insider Monkey 2
Business Wire 2
AD HOC NEWS 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 19
Analyst action 2
Guidance 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
AD HOC NEWS Direct company coverage

Harmony Biosciences Stock - Analyst consensus and technical backdrop

Harmony Biosciences (HRMY) currently holds a "Hold" consensus from Wall Street analysts, trading in a defined range on Nasdaq. The stock closed at $33.28 on June 18, 2026, with analysts showing a cautious balance between buy, hold, and sell ratings. The company's primary revenue

Tone
Neutral 50/100
Event
Analyst action
Published
20 Jun 2026 18:39
Source
AD HOC NEWS
TradingKey Direct company coverage

Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Harmony Biosciences Holdings Inc (HRMY), noting its current valuation score of 8.08 and its ranking in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 13.36, which is significantly below its recent high

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 19:39
Source
TradingKey
TradingKey Direct company coverage

Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Harmony Biosciences Holdings Inc's (HRMY) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also presents institutional shareholding data over several quarters, incl

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 19:39
Source
TradingKey
TradingKey Direct company coverage

Harmony Biosciences Holdings Inc

The article provides a revenue breakdown for Harmony Biosciences Holdings Inc (HRMY), including market capitalization, P/E ratio, and stock performance. It notes that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company,

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 19:39
Source
TradingKey
Stock Traders Daily Direct company coverage

Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Harmony Biosciences Holdings Inc. (HRMY) using AI models to identify trading strategies across different risk profiles and holding periods. It highlights a strong near and mid-term sentiment, a significant risk

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 21:08
Source
Stock Traders Daily
Market source Direct company coverage

Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance

Harmony Biosciences (HRMY) is gaining attention after announcing new Pitolisant data presentations and reaffirming its guidance, leading to a 16.75% share price return in the last 30 days. Despite this short-term momentum, the stock has a modest 5.61% one-year return and a 10.2%

Tone
Positive 66/100
Event
Guidance
Published
12 Jun 2026 14:09
Source
Market source
Stock Titan Direct company coverage

Six narcolepsy and hypersomnia studies from Harmony at SLEEP 2026

Harmony Biosciences (Nasdaq: HRMY) announced that six of its abstracts focusing on narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at the SLEEP 2026 annual meeting. These presentations include analyses of Pitolisant's effects on sleep patterns, re

Tone
Positive 60/100
Event
Market update
Published
12 Jun 2026 06:09
Source
Stock Titan
Insider Monkey Direct company coverage

Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?

Harmony Biosciences Holdings, Inc. (HRMY) is presented as a compelling investment opportunity due to its undervaluation, strong performance of its flagship drug WAKIX, and promising growth pipeline. The company exhibits robust financial health with high gross margins and self-fun

Tone
Positive 70/100
Event
Market update
Published
11 Jun 2026 14:40
Source
Insider Monkey
Stock Titan Direct company coverage

HRMY (NASDAQ) affiliate: option exercise 27,960 shares; Kapadia sells 54,646

Harmony Biosciences Holdings, Inc. (HRMY) affiliate reported a Form 144 filing detailing the exercise of options for 27,960 shares and the sale of 54,646 common shares by Sandip Kapadia across several transactions in May and June 2026. The filing provides specific dates, share co

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

HRMY affiliate files Rule 144 sale notice (NASDAQ: HRMY) for option exercises

Harmony Biosciences Holdings, Inc. (HRMY) submitted a Rule 144 notice for proposed common stock sales related to option exercises on June 5, 2026. The filing indicates recent dispositions of 7,064 shares for $233,232.09 on June 4, 2026, and 45,481 shares for $1,433,056.28 on May

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Sandip Kapadia files Form 144 proposing sale of 45,481 HRMY shares (HRMY)

Sandip Kapadia has filed a Form 144 indicating a proposed sale of 45,481 shares of Harmony Biosciences Holdings, Inc. (HRMY). The filing details a completed sale on May 8, 2026, for an aggregate amount of $1,433,056.28, and a planned transaction tied to an option exercise under a

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 20:08
Source
Stock Titan
Stock Traders Daily Direct company coverage

Technical Reactions to HRMY Trends in Macro Strategies

This article from Stock Traders Daily provides a technical analysis of Harmony Biosciences Holdings Inc. (NASDAQ: HRMY), highlighting a strong near and mid-term sentiment that could extend to the long term. It identifies a mid-channel oscillation pattern and offers three distinct

Tone
Positive 72/100
Event
Market update
Published
04 Jun 2026 19:38
Source
Stock Traders Daily
Business Wire Direct company coverage

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences (Nasdaq: HRMY) announced its management team will attend two investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026. Webcasts of the fireside chats will

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 12:10
Source
Business Wire
Investing.com Direct company coverage

H.C. Wainwright reiterates Harmony Biosciences stock rating at buy

H.C. Wainwright maintained a Buy rating and a $55.00 price target for Harmony Biosciences (NASDAQ:HRMY) despite the company missing first-quarter 2026 revenue and GAAP EPS consensus estimates. The miss was primarily due to high licensing expenses, but Harmony Biosciences remains

Tone
Positive 60/100
Event
Earnings
Published
22 May 2026 21:09
Source
Investing.com
Stock Titan Direct company coverage

HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms

This page on StockTitan provides a comprehensive collection of SEC filings for Harmony Biosciences Holdings, Inc. (HRMY), including 10-K, 10-Q, 8-K forms, and insider trading reports. Each filing is accompanied by an AI-generated summary, impact score, and sentiment analysis. Rec

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 14:11
Source
Stock Titan
StreetInsider Direct company coverage

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a price target of $55.00 for the company. The full article content is only available to premium subscribers.

Tone
Positive 71/100
Event
Analyst action
Published
22 May 2026 11:08
Source
StreetInsider
Quantisnow Direct company coverage

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences reported its Q1 financial results and reaffirmed its 2026 net revenue guidance of over $1 billion. The company also reinforced its strategic priorities for 2026. This announcement indicates the company's confidence in its future financial performance and strat

Tone
Positive 72/100
Event
Earnings
Published
21 May 2026 07:41
Source
Quantisnow
MyChesCo Direct company coverage

Harmony Revenue Rises as WAKIX Franchise Expands

Harmony Biosciences reported a 17% revenue increase for its narcolepsy drug WAKIX in the first quarter, reaching $215.4 million, and reaffirmed its full-year revenue guidance between $1 billion and $1.04 billion. The company is actively expanding its WAKIX franchise through paten

Tone
Positive 65/100
Event
Earnings
Published
20 May 2026 23:10
Source
MyChesCo
Stock Titan Direct company coverage

Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price

Harmony Biosciences director Juan A. Sabater was granted 21,872 stock options with an exercise price of $30.76 per share, vesting on the earlier of May 14, 2027, or the next annual meeting, provided he continues service. These options expire on May 14, 2036. This transaction is a

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 13:10
Source
Stock Titan
www.sharewise.com Direct company coverage

A beaten-down biotech just lost a meaningful backer — should you care?

Bridge City Capital, LLC, has fully divested its investment in Harmony Biosciences Holdings (NASDAQ:HRMY) during the first quarter of 2026, selling all 237,103 shares for an estimated $7.77 million. Harmony Biosciences, a healthcare company, focuses on developing treatments for r

Tone
Negative 29/100
Event
Earnings
Published
20 May 2026 02:09
Source
www.sharewise.com
Stock Titan Direct company coverage

Harmony Biosciences (HRMY) director receives 21,872-share stock option grant

Harmony Biosciences director Linda M. Szyper was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. This grant serves as compensation, not an open-market purchase, and vests fully on the earlier of May 14, 2027, or the next annual m

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 07:10
Source
Stock Titan
Stock Titan Direct company coverage

Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3

Harmony Biosciences Holdings, Inc. director Germano Geno J has filed an initial Form 3 with the SEC, which officially lists him as a reporting person for the company. This filing is a mandatory first insider ownership report for company officers, directors, and large shareholders

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Harmony Biosciences (HRMY) director granted 21,231 stock options

Harmony Biosciences Holdings, Inc. director Germano Geno J was granted 21,231 stock options as equity compensation. These options, with an exercise price of $30.76 per share and an expiration date of May 14, 2036, will vest in 36 equal monthly installments starting on June 14, 20

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Harmony Biosciences director granted 21,872 options | HRMY Insider Trading

Harmony Biosciences director Philip Ron M was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. The options will vest in full by May 14, 2027, or the date of the next annual meeting, contingent on his continued service. This transa

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 20:39
Source
Stock Titan